Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients.
As part of the initial research project, Tempus will use its Tempus O platform to ingest and structure clinical data from the cancer center's electronic health record. Tempus also will provide next generation sequencing and analysis for a subset of patients in order to identify actionable gene alterations. Datasets often are small and sometimes disorganized. In order to usher in the age of precision medicine, Tempus built a series of data pipelines to collect, cleanse, and analyze data, at scale.
"Empowering Vanderbilt-Ingram researchers and physicians with data, tools and evidence to help inform care and accelerate discoveries that benefit patients is a top priority," said Jennifer Pietenpol, PhD, executive vice president for Research at Vanderbilt University Medical Center and director of VICC. "Collaborating with Tempus will allow the Vanderbilt-Ingram team to gain a deeper understanding of a patient's cancer and its genetic and molecular drivers with a goal of improving patient outcomes."